Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rada Petrinjac-Nenadic

Neurology Memphis, TN Medical Doctor

NPI 1891911954 CMS profile 312822

5100 Sanderlin Ave, Suite 2100, Memphis, TN 38117

Open in the dashboard

General payments

$13,661

764 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rada Petrinjac-Nenadic of Memphis, TN is reported in the CMS Open Payments database as having received $13,661 across 764 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,085 98
2024 General $2,635 124
2023 General $2,065 110
2022 General $2,149 113
2021 General $2,038 137
2020 General $1,597 107
2019 General $1,093 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rada Petrinjac-Nenadic
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rada Petrinjac-Nenadic were reported at $2,085. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rada Petrinjac-Nenadic Neurology median Middle half National median
2019 $1,093 $474 $118–$2,177 $163
2020 $1,597 $367 $82–$2,309 $114
2021 $2,038 $438 $104–$2,547 $132
2022 $2,149 $442 $103–$2,388 $149
2023 $2,065 $464 $119–$2,312 $160
2024 $2,635 $468 $119–$2,323 $164
2025 $2,085 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $1,433 72 payments
  2. Novartis Pharmaceuticals Corporation $1,321 80 payments
  3. Alexion Pharmaceuticals, Inc. $1,221 55 payments
  4. AbbVie, Inc. $743 53 payments
  5. Argenx US, Inc. $629 23 payments
  6. Eisai Inc. $591 26 payments
  7. Lundbeck LLC $544 23 payments
  8. Pfizer Inc. $537 45 payments
  9. Allergan Inc. $502 43 payments
  10. Biogen, Inc. $498 22 payments
  11. Other $5,642 322 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,515 751 payments
  2. Education $106 11 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41 2 payments
Products named General payments · program years 2019–2025
  1. ULTOMIRIS $691 27 payments
  2. KESIMPTA Neuroscience $582 34 payments
  3. Briviact $493 33 payments
  4. UPLIZNA $484 26 payments
  5. NURTEC ODT $449 41 payments
  6. BOTOX $448 33 payments
  7. KESIMPTA Neurology $430 24 payments
  8. Hizentra $418 26 payments
  9. Soliris $414 23 payments
  10. Leqembi $405 15 payments
  11. Other $9,179 519 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

2,548

Median for Neurology: 833

Drug cost

$570,410

Median for Neurology: $202,670

Branded share of claims

14.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Betaseron Interferon Beta-1b Brand 15 $145,941
Dimethyl Fumarate Generic 37 $67,251
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 21 $48,280
Nurtec Odt Rimegepant Sulfate Brand 28 $40,914
Qulipta Atogepant Brand 25 $34,938
Briviact Brivaracetam Brand 20 $33,863
Droxidopa Generic 21 $26,951
Aptiom Eslicarbazepine Acetate Brand 19 $26,481
Glatiramer Acetate Generic 12 $21,314
Ubrelvy Ubrogepant Brand 17 $19,329

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$1,591,042

Of which drugs: $1,408,433

Medicare patients

493

Average age 72

Services billed

28,874

268 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 48%
Ischemic heart disease 41%
Depression 40%
Chronic kidney disease 38%
Heart failure 36%
Alzheimer's or dementia 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg J1576 Office 32 12,830 $681,840
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 15 5,430 $184,346
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 31 170 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Rystiggo
$259 — —
Leqembi
$255 — —
Nayzilam
$228 13 —
ULTOMIRIS
$205 — —
INGREZZA
$192 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

764 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record